Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in Kampala, Uganda

Judith A. Hahn, Marissa Maier, Jayne Byakika-Tusiime, Jessica H. Oyugi, David Bangsberg

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Generic, low-cost, nevirapine (NVP)-based antiretroviral therapy (ART) has improved survival in HIV-infected individuals living in resource-limited settings. However, there is concern about the potential hepatotoxicity of these regimens. Methods: The authors conducted a prospective study of persons initiating self-pay Triomune or Maxivir therapy in Kampala, Uganda. Results: The 97 study participants were predominantly women (64%), median age was 35 (interquartile range [IQR] 30-40), median CD4 at baseline was 56 cells/mm 3 (IQR 8-138), and 19% had lifetime alcohol problems (CAGE < 2). Severe liver enzyme elevations (LEEs) of grade 3-4 were rare (2.2%); however, 1 patient died in the setting of grade 4 LEEs. Grade 1-4 LEEs occurred among 22.2% of participants, and 9.8% had new grade 1-4 LEEs after the initiation of treatment. Discussion: The authors found that LEEs were common but that severe hepatotoxicity in persons initiating NVP-based ART was infrequent yet potentially life-threatening. Monitoring for NVP-related severe hepatic toxicity should be part of expanding antiretroviral treatment programs in resource-limited settings.

Original languageEnglish (US)
Pages (from-to)83-86
Number of pages4
JournalJournal of the International Association of Physicians in AIDS Care
Volume6
Issue number2
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Nevirapine
Uganda
Liver
Enzymes
Therapeutics
Alcohols
HIV
Prospective Studies
Costs and Cost Analysis
Survival

Keywords

  • antiretroviral therapy
  • hepatotoxicity
  • HIV
  • Uganda

ASJC Scopus subject areas

  • Immunology
  • Dermatology
  • Infectious Diseases

Cite this

Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in Kampala, Uganda. / Hahn, Judith A.; Maier, Marissa; Byakika-Tusiime, Jayne; Oyugi, Jessica H.; Bangsberg, David.

In: Journal of the International Association of Physicians in AIDS Care, Vol. 6, No. 2, 06.2007, p. 83-86.

Research output: Contribution to journalArticle

@article{68922457a86546b69492a3aa648efc21,
title = "Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in Kampala, Uganda",
abstract = "Background: Generic, low-cost, nevirapine (NVP)-based antiretroviral therapy (ART) has improved survival in HIV-infected individuals living in resource-limited settings. However, there is concern about the potential hepatotoxicity of these regimens. Methods: The authors conducted a prospective study of persons initiating self-pay Triomune or Maxivir therapy in Kampala, Uganda. Results: The 97 study participants were predominantly women (64{\%}), median age was 35 (interquartile range [IQR] 30-40), median CD4 at baseline was 56 cells/mm 3 (IQR 8-138), and 19{\%} had lifetime alcohol problems (CAGE < 2). Severe liver enzyme elevations (LEEs) of grade 3-4 were rare (2.2{\%}); however, 1 patient died in the setting of grade 4 LEEs. Grade 1-4 LEEs occurred among 22.2{\%} of participants, and 9.8{\%} had new grade 1-4 LEEs after the initiation of treatment. Discussion: The authors found that LEEs were common but that severe hepatotoxicity in persons initiating NVP-based ART was infrequent yet potentially life-threatening. Monitoring for NVP-related severe hepatic toxicity should be part of expanding antiretroviral treatment programs in resource-limited settings.",
keywords = "antiretroviral therapy, hepatotoxicity, HIV, Uganda",
author = "Hahn, {Judith A.} and Marissa Maier and Jayne Byakika-Tusiime and Oyugi, {Jessica H.} and David Bangsberg",
year = "2007",
month = "6",
doi = "10.1177/1545109707299356",
language = "English (US)",
volume = "6",
pages = "83--86",
journal = "Journal of the International Association of Physicians in AIDS Care",
issn = "1545-1097",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in Kampala, Uganda

AU - Hahn, Judith A.

AU - Maier, Marissa

AU - Byakika-Tusiime, Jayne

AU - Oyugi, Jessica H.

AU - Bangsberg, David

PY - 2007/6

Y1 - 2007/6

N2 - Background: Generic, low-cost, nevirapine (NVP)-based antiretroviral therapy (ART) has improved survival in HIV-infected individuals living in resource-limited settings. However, there is concern about the potential hepatotoxicity of these regimens. Methods: The authors conducted a prospective study of persons initiating self-pay Triomune or Maxivir therapy in Kampala, Uganda. Results: The 97 study participants were predominantly women (64%), median age was 35 (interquartile range [IQR] 30-40), median CD4 at baseline was 56 cells/mm 3 (IQR 8-138), and 19% had lifetime alcohol problems (CAGE < 2). Severe liver enzyme elevations (LEEs) of grade 3-4 were rare (2.2%); however, 1 patient died in the setting of grade 4 LEEs. Grade 1-4 LEEs occurred among 22.2% of participants, and 9.8% had new grade 1-4 LEEs after the initiation of treatment. Discussion: The authors found that LEEs were common but that severe hepatotoxicity in persons initiating NVP-based ART was infrequent yet potentially life-threatening. Monitoring for NVP-related severe hepatic toxicity should be part of expanding antiretroviral treatment programs in resource-limited settings.

AB - Background: Generic, low-cost, nevirapine (NVP)-based antiretroviral therapy (ART) has improved survival in HIV-infected individuals living in resource-limited settings. However, there is concern about the potential hepatotoxicity of these regimens. Methods: The authors conducted a prospective study of persons initiating self-pay Triomune or Maxivir therapy in Kampala, Uganda. Results: The 97 study participants were predominantly women (64%), median age was 35 (interquartile range [IQR] 30-40), median CD4 at baseline was 56 cells/mm 3 (IQR 8-138), and 19% had lifetime alcohol problems (CAGE < 2). Severe liver enzyme elevations (LEEs) of grade 3-4 were rare (2.2%); however, 1 patient died in the setting of grade 4 LEEs. Grade 1-4 LEEs occurred among 22.2% of participants, and 9.8% had new grade 1-4 LEEs after the initiation of treatment. Discussion: The authors found that LEEs were common but that severe hepatotoxicity in persons initiating NVP-based ART was infrequent yet potentially life-threatening. Monitoring for NVP-related severe hepatic toxicity should be part of expanding antiretroviral treatment programs in resource-limited settings.

KW - antiretroviral therapy

KW - hepatotoxicity

KW - HIV

KW - Uganda

UR - http://www.scopus.com/inward/record.url?scp=35549000405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35549000405&partnerID=8YFLogxK

U2 - 10.1177/1545109707299356

DO - 10.1177/1545109707299356

M3 - Article

C2 - 17537997

AN - SCOPUS:35549000405

VL - 6

SP - 83

EP - 86

JO - Journal of the International Association of Physicians in AIDS Care

JF - Journal of the International Association of Physicians in AIDS Care

SN - 1545-1097

IS - 2

ER -